Clinical trial
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory…
NCT00193557 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193557 |
|---|---|
| Title | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma |
| Official title | Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 40 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: